These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 27460780

  • 1. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, Li P.
    BMC Complement Altern Med; 2016 Jul 26; 16():246. PubMed ID: 27460780
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.
    PLoS One; 2015 Jul 26; 10(5):e0126027. PubMed ID: 25938778
    [Abstract] [Full Text] [Related]

  • 3. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M, Wen Y, Yang L, Wu X, Lu X, Zhang B, Huang W, Li P.
    Trials; 2016 May 23; 17(1):259. PubMed ID: 27216240
    [Abstract] [Full Text] [Related]

  • 4. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
    Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL.
    Trials; 2019 Dec 21; 20(1):756. PubMed ID: 31864393
    [Abstract] [Full Text] [Related]

  • 5. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM, Zhang Y, He XH, Chen HD, Wang ZF, Guo J, Wang XM, Gao ZZ, Wang JP, Liu W, Zhao LH, Tong XL.
    Trials; 2018 Mar 27; 19(1):200. PubMed ID: 29587863
    [Abstract] [Full Text] [Related]

  • 6. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.
    Diabetes Care; 2005 Nov 27; 28(11):2728-32. PubMed ID: 16249547
    [Abstract] [Full Text] [Related]

  • 7. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
    Wang M, Wang Z, Zhou J, Sun W, Wang Y, Han M, Yang H, Liu WJ, Wang Y.
    Trials; 2018 Jul 17; 19(1):389. PubMed ID: 30016983
    [Abstract] [Full Text] [Related]

  • 8. Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial.
    Liu M, Di YM, Zhang L, Yang L, Zhang L, Chen J, Wang R, Xie X, Lan F, Xie L, Huang J, Zhang AL, Xue CC, Liu X.
    Front Endocrinol (Lausanne); 2024 Jul 17; 15():1334609. PubMed ID: 38390199
    [Abstract] [Full Text] [Related]

  • 9. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R, Wei F, Qu L, Bai L, Li J, Li F, Yan W, Wang Q, Wei J.
    Trials; 2020 Nov 23; 21(1):951. PubMed ID: 33228726
    [Abstract] [Full Text] [Related]

  • 10. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P, PRIORITY investigators.
    Lancet Diabetes Endocrinol; 2020 Apr 23; 8(4):301-312. PubMed ID: 32135136
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in Rats.
    Zhao T, Sun S, Zhang H, Huang X, Yan M, Dong X, Wen Y, Wang H, Lan HY, Li P.
    PLoS One; 2016 Apr 23; 11(1):e0147693. PubMed ID: 26807792
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.
    Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K.
    Diabetes Care; 2011 Mar 23; 34(3):691-6. PubMed ID: 21273494
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease.
    Liao T, Zhao K, Huang Q, Tang S, Chen K, Xie C, Zhang C, Gan W.
    Medicine (Baltimore); 2020 Jul 31; 99(31):e21137. PubMed ID: 32756091
    [Abstract] [Full Text] [Related]

  • 14. The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.
    Tanabe J, Ogura Y, Nakabayashi M, Nagai Y, Watanabe S, Sugaya T, Ohata K, Ichikawa D, Inoue K, Hoshino S, Kimura K, Shibagaki Y, Ono Y, Kamijo-Ikemori A.
    Kidney Blood Press Res; 2019 Jul 31; 44(6):1476-1492. PubMed ID: 31734667
    [Abstract] [Full Text] [Related]

  • 15. Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression.
    Zhao H, Li X, Zhao T, Zhang H, Yan M, Dong X, Chen P, Ma L, Li P.
    PLoS One; 2017 Jul 31; 12(2):e0171475. PubMed ID: 28182710
    [Abstract] [Full Text] [Related]

  • 16. Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.
    Tanabe J, Ogura Y, Kosaki K, Nagai Y, Sugaya T, Ohata K, Watanabe S, Ichikawa D, Inoue K, Hoshino S, Kimura K, Maeda S, Shibagaki Y, Kamijo-Ikemori A.
    J Diabetes Res; 2020 Jul 31; 2020():7614035. PubMed ID: 32405506
    [Abstract] [Full Text] [Related]

  • 17. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.
    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H.
    Diabetes Metab Res Rev; 2006 Jul 31; 22(5):385-9. PubMed ID: 16506273
    [Abstract] [Full Text] [Related]

  • 18. [L-type fatty acid binding protein (L-FABP) and kidney disease].
    Kamijo-Ikemori A, Sugaya T, Kimura K.
    Rinsho Byori; 2014 Feb 31; 62(2):163-70. PubMed ID: 24800492
    [Abstract] [Full Text] [Related]

  • 19. Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats.
    Zhao T, Zhang H, Yin X, Zhao H, Ma L, Yan M, Peng L, Wang Q, Dong X, Li P.
    Biomed Pharmacother; 2020 Sep 31; 129():110325. PubMed ID: 32535383
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of the Shenzhuo formula in the treatment of patients with macroalbuminuria secondary to diabetic kidney disease: protocol update and statistical analysis plan.
    Wei Y, Huang YS, Yang Z, Wang X, Li Y, Zhang Y, Zhao LH, Tong X.
    Trials; 2022 Jan 20; 23(1):61. PubMed ID: 35057843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.